C2N 8E12

Drug Profile

C2N 8E12

Alternative Names: ABBV-8E12; C2N-8E12

Latest Information Update: 25 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator C2N Diagnostics
  • Developer AbbVie; C2N Diagnostics
  • Class Antibodies; Antiparkinsonians; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progressive supranuclear palsy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Progressive supranuclear palsy

Most Recent Events

  • 17 Apr 2018 AbbVie initiates a phase I trial for Progressive Supranuclear Palsy in USA (IV) (NCT03413319)
  • 30 Jan 2018 AbbVie initiates a phase II trial for Progressive Supranuclear Palsy in January 2018 , (NCT03391765)
  • 29 Jan 2018 AbbVie plans a phase I trial for Progressive Supranuclear Palsy in February 2018 (IV) , (NCT03413319)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top